sabato, 2 maggio 2026

Notizie AIOM – anno XV

7 Dicembre 2017

Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial

Patients with advanced sarcomas have a poor prognosis and few treatment options that improve overall survival. Chemotherapy and targeted therapies offer short-lived disease control. We assessed pembrolizumab, an anti-PD-1 antibody, for safety and activity in patients with ...
Leggi tutto

7 Dicembre 2017

Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study

Results from retrospective studies indicate that selecting individuals for low-dose CT lung cancer screening on the basis of a highly predictive risk model is superior to using criteria similar to those used in the National Lung Screening Trial (NLST; age, pack-year, and ...
Leggi tutto

7 Dicembre 2017

4 dicembre 2017 – FDA approva il primo regime di trattamento per l’HIV con due soli medicinali

7 Dicembre 2017

4 dicembre 2017 – Carenza Capecitabine Medac – modalità di richiesta d’importazione dall’estero

7 Dicembre 2017

6 dicembre 2017 – Linee guida della Commissione Europea sulle GMP per i prodotti medicinali per terapie avanzate (ATMP)

7 Dicembre 2017

7 dicembre 2017 – Pubblicato il Bando AIFA 2017 per la ricerca indipendente sui farmaci

7 Dicembre 2017

7 dicembre 2017 – AIFA a supporto dell’innovazione nell’Info day dell’EU-Innovation Network

7 Dicembre 2017

FDA Approves New Oral Solution for Colonoscopy Preparation

December 4, 2017 - The U.S. Food and Drug Administration (FDA) has granted Ferring Pharmaceuticals Inc approval to market a combination sodium picosulfate, magnesium oxide, and anhydrous citric acid oral solution for cleansing the colon in adults undergoing a colonoscopy. ...
Leggi tutto

7 Dicembre 2017

FDA Grants Bevacizumab Full Approval for Glioblastoma

December 5, 2017 - The FDA has granted bevacizumab a full approval for the treatment of adult patients with glioblastoma that progressed following prior therapy, according to Genentech, the manufacturer of the VEGF inhibitor. Bevacizumab previously received an accelerated ...
Leggi tutto

7 Dicembre 2017

FDA Grants Priority Review to Maintenance Rucaparib for Ovarian Cancer

December 6, 2017 - The FDA has granted a priority review to a supplemental new drug application (sNDA) for rucaparib for use as a maintenance treatment for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial ...
Leggi tutto